HUP0100349A2 - Pharmaceutical compositions containing antihyperlipidemic statin-lp(a) inhibitor - Google Patents

Pharmaceutical compositions containing antihyperlipidemic statin-lp(a) inhibitor

Info

Publication number
HUP0100349A2
HUP0100349A2 HU0100349A HUP0100349A HUP0100349A2 HU P0100349 A2 HUP0100349 A2 HU P0100349A2 HU 0100349 A HU0100349 A HU 0100349A HU P0100349 A HUP0100349 A HU P0100349A HU P0100349 A2 HUP0100349 A2 HU P0100349A2
Authority
HU
Hungary
Prior art keywords
statin
antihyperlipidemic
inhibitor
pharmaceutical compositions
compositions containing
Prior art date
Application number
HU0100349A
Other languages
Hungarian (hu)
Inventor
Charles Larry Bisgaier
Roger Schofield Newton
Randy Ranjee Ramharack
Original Assignee
Warner-Lambert Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Co. filed Critical Warner-Lambert Co.
Publication of HUP0100349A2 publication Critical patent/HUP0100349A2/en
Publication of HUP0100349A3 publication Critical patent/HUP0100349A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány egy olyan kombinációra vonatkozik, amely egyrészt egy, akis sűrűségű lipoproteinek (LDL) plazmakoncentrációját csökkentőhatású statin vegyületből, másrészt pedig egy olyan vegyületből áll,amely vegyület gátolja a lipoprotein (a)[Lp (a)] képződését, amely Lp(a) az LDL-nek egy olyan, módosított formája, amelyre a statinoknaknincs hatásuk. A kombináció felhasználható vascularis betegségek és diabetesmellitus kezelésére. ÓThe invention relates to a combination consisting on the one hand of a statin compound that reduces the plasma concentration of low-density lipoproteins (LDL) and on the other hand of a compound that inhibits the formation of lipoprotein (a) [Lp (a)], which is Lp(a) a modified form of LDL on which statins have no effect. The combination can be used to treat vascular diseases and diabetes mellitus. HE

HU0100349A 1997-12-12 1998-11-04 Pharmaceutical compositions containing antihyperlipidemic statin-lp(a) inhibitor HUP0100349A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6943297P 1997-12-12 1997-12-12
PCT/US1998/023480 WO1999030706A1 (en) 1997-12-12 1998-11-04 ANTIHYPERLIPIDEMIC STATIN-LP(a) INHIBITOR COMBINATIONS

Publications (2)

Publication Number Publication Date
HUP0100349A2 true HUP0100349A2 (en) 2001-07-30
HUP0100349A3 HUP0100349A3 (en) 2002-02-28

Family

ID=22088939

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0100349A HUP0100349A3 (en) 1997-12-12 1998-11-04 Pharmaceutical compositions containing antihyperlipidemic statin-lp(a) inhibitor

Country Status (14)

Country Link
EP (1) EP1037623A1 (en)
JP (1) JP2003524582A (en)
KR (1) KR20010033017A (en)
AU (2) AU1306099A (en)
BR (1) BR9813539A (en)
CA (1) CA2299397A1 (en)
HU (1) HUP0100349A3 (en)
IL (1) IL134364A0 (en)
IS (1) IS5385A (en)
NO (1) NO20002965D0 (en)
NZ (1) NZ502874A (en)
PL (1) PL343851A1 (en)
WO (1) WO1999030706A1 (en)
ZA (1) ZA9811349B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2277112C (en) 1997-01-07 2008-08-26 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
EP1076091A1 (en) * 1999-08-09 2001-02-14 Universite Catholique De Louvain Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds
US20030036504A1 (en) * 2000-01-10 2003-02-20 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia
WO2001058443A1 (en) * 2000-02-10 2001-08-16 Takeda Chemical Industries, Ltd. TNF- α INHIBITORS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2016467A1 (en) * 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
WO1993013801A1 (en) * 1992-01-17 1993-07-22 The Procter & Gamble Company Treatment for atherosclerosis
WO1993016690A1 (en) * 1992-02-25 1993-09-02 Warner-Lambert Company Cytoprotective compositions containing pyruvate and antioxidants
US5720963A (en) * 1994-08-26 1998-02-24 Mary Kay Inc. Barrier disruption treatments for structurally deteriorated skin
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
EP0738510A3 (en) * 1995-04-20 2005-12-21 L'oreal Use of a HMG-CoA reductase inhibitor as an anti-ageing agent and as an anti-acne agent. Composition comprising at least one HMG-CoA reductase inhibitor and at least one active substance with scaling properties.
EP0904082A4 (en) * 1996-04-17 2001-09-26 Merck & Co Inc Combination therapy for reducing the risks associated with cardiovascular disease
NZ503982A (en) * 1997-12-12 2002-03-28 Warner Lambert Co Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus

Also Published As

Publication number Publication date
CA2299397A1 (en) 1999-06-24
BR9813539A (en) 2000-10-10
EP1037623A1 (en) 2000-09-27
PL343851A1 (en) 2001-09-10
AU2003244047A1 (en) 2003-09-25
ZA9811349B (en) 1999-06-14
NO20002965L (en) 2000-06-09
KR20010033017A (en) 2001-04-25
WO1999030706A1 (en) 1999-06-24
IL134364A0 (en) 2001-04-30
HUP0100349A3 (en) 2002-02-28
NZ502874A (en) 2004-03-26
AU1306099A (en) 1999-07-05
IS5385A (en) 2000-02-25
NO20002965D0 (en) 2000-06-09
JP2003524582A (en) 2003-08-19

Similar Documents

Publication Publication Date Title
BR9814327A (en) Thiourea and benzamide compounds, compositions and processes for the treatment or prevention of inflammatory diseases and arteriosclerosis
BR0112799A (en) Pharmaceutical composition, process for preparation and use thereof, assembly and process for treating obesity, use of a lipase inhibitor and bile acid sequestrant, and process for treating or preventing gastrointestinal side effects
DE69837324D1 (en) TREATMENT OF MULTIPLE SCLEROSIS BY USING COPOLYMER-1
HUP0004396A2 (en) Pharmaceutical compositions containing hydroxylated cholesterol lowering agent as inhibitor of lipoprotein oxidation
HUP0102550A2 (en) Compounds having ige response affecting properties
HUP0401501A2 (en) Treating or preventing vascular inflammation using pharmaceutical compositions containing sterol absorption inhibitor(s)
BG103793A (en) COMBINED THERAPY USING BENZOTHIAPINS INHIBITING THE ILEAL BILE ACID TRANSPORT AND HMG Co-A REDUCTASE INHIBITORS
EE03383B1 (en) Combination of a cholesterol biosynthesis inhibitor and a β-lactam inhibitor of cholesterol absorption
UA26213C2 (en) MEANS FOR PREVENTION AND TREATMENT OF OSTEOPOROSIS AND PHARMACEUTICAL COMPOSITION AND THEIR BASES
EA200501805A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING THE ENZYME INHIBITOR DIPEPTIDYLPEPIDASE
BR9916565A (en) Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
HUP0003103A2 (en) Combination therapy comprising amlodipine and a statin compound
ATE265857T1 (en) PHARMACEUTICAL OR DIETETIC COMPOSITION FOR THE PREVENTION OR TREATMENT OF HYPEROXALUria
FI973828A0 (en) Compounds and compositions for administering the active ingredients
HUP0103160A2 (en) Pharmaceutical compositions for treating pulmonary diseases containing pde4 inhibitor
DE69827777D1 (en) Delayed-release compositions for the treatment of hyperlipidemia
BR9806060A (en) Compound, pharmaceutical composition and processes to treat a patient suffering from a sick condition, to inhibit factor xa, and to inhibit thrombin formation.
ATE451369T1 (en) PIPERIDINOPYRIMIDEINDIPEPTIDYLPEPTIDASE INHIBITOR N FOR THE TREATMENT OF DIABETES
AR067030A2 (en) PHARMACEUTICAL COMPOSITIONS
PT951473E (en) NEW DERIVATIVES OF CICLOSPORIN ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
HUP0402506A2 (en) A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
DE69811062D1 (en) POLYAROMATIC ANTIVIRAL COMPOSITIONS
HUP0401614A2 (en) Pharmaceutical compositions containing pde4 inhibitor and anticolinergic agent and use thereof
HUP0004271A2 (en) Compositions comprising amylin or amylin agonist for treating obesity
ES2113957T3 (en) PHARMACEUTICAL PREPARATION CONTAINING A URICOSURIC AGENT AND AN EXCITING AMINO ACID ANTAGONIST.